查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884079

GLP-2类似物市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032）

GLP-2 Analogs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

GLP-2类似物市场成长驱动因子

随着短肠症候群 (SBS) 和其他胃肠道疾病在全球日益加重，全球GLP-2类似物市场持续快速成长。最新评估显示，2024年市场规模将达到10.5亿美元，主要驱动因素包括诊断率的提高、肠道功能障碍管理水平的改善以及GLP-2类似物疗法在临床上的应用日益广泛。在对有效SBS疗法的强劲需求以及长效製剂创新技术的推动下，预计2025年市场规模将增长至12亿美元，到2032年将达到28.3亿美元，反映出全球应用范围的显着扩大。

GLP-2 类似物模拟天然 GLP-2 激素，促进肠道生长，增强吸收，并减少对肠外营养的依赖。这些疗法已成为短肠症候群 (SBS) 治疗的基石，改善患者预后，并减少因慢性肠道功能障碍而住院的需求。随着美国、欧洲和亚太地区研发投入的增加，对这些药物的需求持续成长。

市场动态

驱动因素

一个关键驱动因素是短肠症候群 (SBS) 盛行率的不断上升，其病因包括先天性异常、胃肠道手术、创伤或导致肠道缺损的疾病。存活率的提高和公众意识的增强正在扩大需要长期治疗的 SBS 患者群体。根据《临床营养实务（2025）》预测，到2024年，短肠症候群（SBS）的盛行率预计将达到每10万成年人2.74例，每10万儿童1.67例，这显示全球对有效治疗方法的需求日益增长。由于GLP-2类似物经临床验证可改善肠道吸收，因此在预测期内的需求预计将保持强劲。

限制因子

儘管GLP-2类似物具有许多益处，但高昂的治疗费用仍是一大障碍。特度格鲁肽治疗的年费用超过每位患者40万美元，这限制了低收入地区的患者获得治疗的机会，即使在已开发市场也造成了经济负担。高昂的研发成本也加剧了定价方面的挑战，并可能减缓市场渗透速度。

机会

开发长效GLP-2类似物蕴藏着巨大的机遇，这些类似物旨在每週给药一次，而非每日给药。例如，阿普拉鲁肽和格雷帕鲁肽等产品旨在提高患者的依从性和便利性。泽兰製药的研发管线还包括已展现出显着临床潜力的即用型水性类似物。这预示着下一代疗法的到来，这些疗法将提供更高的疗效和更低的注射频率。

挑战

监管障碍仍然是一项重大挑战，因为新的类似物需要进行复杂的安全性评估。对胃肠道不适、胰臟炎和甲状腺癌等副作用的担忧需要严格的监测和漫长的审批流程。例如，2024年12月，美国FDA对泽兰製药的格雷帕鲁肽发出了完整回覆函（CRL），推迟了上市。

市场趋势

一个显着的趋势是从全肠外营养 (TPN) 转向基于 GLP-2 的治疗。由于併发症风险高且成本高，TPN（传统上是短肠症候群 (SBS) 的主要治疗方法）正越来越多地被旨在改善肠道功能的药物解决方案所取代。此外，正在进行的临床试验正在探索将适应症扩展到 SBS 以外的疾病，包括克罗恩病、溃疡性结肠炎、化疗引起的肠道疾病和移植物抗宿主疾病。

细分市场洞察

依药物分类

特度格鲁肽在 2024 年占据市场主导地位，并凭藉其已证实的安全性、临床疗效和广泛应用，仍然是领先的 GLP-2 类似物。它是第一个被证实能够减少对肠外营养依赖的 GLP-2 类似物。同时，阿普拉鲁肽和格雷帕鲁肽等新兴类似物预计将作为长效替代药物而广受欢迎。

依给药途径

2024年，肠外给药途径占最大市场占有率，因为大多数已核准的GLP-2类似物都是透过注射给药。人们对口服製剂的兴趣日益增长，Entera Bio在2024年取得的良好药物动力学结果表明，口服製剂有望成为更容易使用的替代药物。

按分销管道

由于便利性和广泛的可近性，线上药局和零售药局在2024年引领市场。同时，医院药局在急性短肠症候群（SBS）的治疗中继续发挥至关重要的作用。

区域展望

北美将在2024年占据GLP-2类似物市场的主导地位，市场规模将达到8.1亿美元，这得益于其最高的药物采纳率和已获批准类似物最广泛的临床应用。在美国，特度格鲁肽的专利到期以及一些成功的新临床试验（例如Ironwood公司2024年公布的阿普拉鲁肽III期临床试验结果）将继续推动市场成长。

欧洲凭藉其高水准的研发能力和良好的监管环境，继续保持着强劲的市场占有率。亚太地区正在快速扩张，这得益于日本、中国和韩国罕见疾病研究的增加以及早期临床试验的开展。随着人们对短肠症候群的认识和诊断能力的提高，拉丁美洲和中东及非洲地区正在稳步取得进展。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家短肠症候群盛行率（2024 年）
  • 主要公司产品线分析
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 主要公司的监管和报销情况国家/地区

第五章 全球 GLP-2 类似物市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 按药物分类
    • 特度格鲁肽
    • 其他
  • 市场分析、洞察与预测 - 按给药途径分类
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测 - 依销售管道分类
    • 医院药房
    • 线上和零售药房
  • 市场分析、洞察与预测 - 按地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章北美 GLP-2 类似物市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲 GLP-2 类似物市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区 GLP-2 类似物市场分析、洞察与预测 (2019-2032)

  • 依国家/地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲 GLP-2 类似物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲 GLP-2 类似物市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东和非洲其他地区

第十一章竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 雀巢
    • 武田药品工业株式会社
    • OxThera
    • Zealand Pharma
    • Ironwood
    • 韩美製药株式会社
    • Jaguar Health
    • 默克集团
    • EnteraBio Ltd.
Product Code: FBI113558

Growth Factors of GLP-2 analogs Market

The global GLP-2 analogs market continues to expand rapidly as the burden of short bowel syndrome (SBS) and other gastrointestinal disorders grows worldwide. According to the latest assessment, the market was valued at USD 1.05 billion in 2024, driven by increased diagnosis rates, improving intestinal failure management, and rising clinical acceptance of GLP-2 analog-based therapies. Owing to strong demand for effective SBS treatment options and innovations in long-acting formulations, the market is projected to increase to USD 1.20 billion in 2025, eventually reaching USD 2.83 billion by 2032, reflecting a significant rise in global adoption.

GLP-2 analogs function by mimicking the natural GLP-2 hormone to enhance intestinal growth, promote absorption, and reduce reliance on parenteral nutrition. These therapies have become a cornerstone in managing SBS, offering improved patient outcomes and reducing hospitalization needs associated with chronic intestinal failure. With the U.S., Europe, and Asia Pacific intensifying research and development efforts, the demand for these drugs continues to escalate.

Market Dynamics

Drivers

A primary driver is the increasing prevalence of short bowel syndrome, caused by congenital defects, gastrointestinal surgeries, trauma, or diseases leading to intestinal loss. Rising survival rates and improved awareness have expanded the SBS patient pool requiring long-term treatment. According to Nutrition in Clinical Practice (2025), SBS prevalence in 2024 reached 2.74 per 100,000 adults and 1.67 per 100,000 children, demonstrating a growing global need for effective therapies. As GLP-2 analogs offer clinically proven improvements in intestinal absorption, demand is expected to remain strong across the forecast period.

Restraints

Despite their benefits, high treatment costs remain a significant barrier. The annual cost of Teduglutide therapy exceeds USD 400,000 per patient, limiting accessibility in lower-income regions and creating financial strain even in developed markets. High research and development expenses further contribute to pricing challenges, potentially slowing market penetration.

Opportunities

A promising opportunity lies in the development of long-acting GLP-2 analogs, designed for weekly rather than daily dosing. Products such as Apraglutide and Glepaglutide aim to improve patient compliance and convenience. Zealand Pharma's pipeline, including ready-to-use aqueous analogs, has shown substantial clinical promise, signaling an upcoming wave of next-generation treatments with enhanced efficacy and fewer injections.

Challenges

Regulatory hurdles remain a key challenge as new analogs undergo complex safety evaluations. Concerns over adverse effects-such as gastrointestinal discomfort, pancreatitis, and thyroid cancer-necessitate stringent monitoring and lengthy approval processes. For example, in December 2024, the U.S. FDA issued a complete response letter for Zealand Pharma's Glepaglutide, delaying its entry into the market.

Market Trends

One notable trend is the shift from total parenteral nutrition (TPN) to GLP-2-based therapies. While TPN was historically the primary treatment for SBS, its high complication risks and cost have pushed clinicians toward pharmacological solutions that improve intestinal function. Additionally, ongoing clinical trials are expanding therapeutic indications beyond SBS, with research exploring use in Crohn's disease, ulcerative colitis, chemotherapy-induced enteropathy, and graft-versus-host disease.

Segmentation Insights

By Drug

Teduglutide dominated the market in 2024 and remains the leading GLP-2 analog due to proven safety, clinical efficacy, and widespread adoption. It is the first GLP-2 analog demonstrating reduced dependence on parenteral support. Meanwhile, emerging analogs such as Apraglutide and Glepaglutide are projected to gain traction as long-acting alternatives.

By Route of Administration

The parenteral segment held the largest share in 2024, as most approved GLP-2 analogs are administered by injection. Oral formulations are gaining interest, with Entera Bio's 2024 positive pharmacokinetic results indicating future potential for easier-to-use alternatives.

By Distribution Channel

Online and retail pharmacies led the market in 2024 due to convenience and broad accessibility, while hospital pharmacies remain essential for acute SBS management.

Regional Outlook

North America dominated the GLP-2 analogs market with USD 0.81 billion in 2024, representing the highest adoption and strongest clinical usage of approved analogs. In the U.S., patent expiry for Teduglutide and new clinical trial successes, such as Ironwood's 2024 Apraglutide phase 3 results, continue to stimulate growth.

Europe maintains a strong share due to high research output and supportive regulatory environments. The Asia Pacific region is expanding rapidly, supported by increasing rare disease research and early-stage clinical trials in Japan, China, and South Korea. Latin America and the Middle East & Africa show steady progression as awareness and diagnostic capabilities improve.

Conclusion

The global GLP-2 analogs market is poised for robust growth through 2032 as clinical innovation, long-acting formulations, and expanding disease indications transform SBS management. With the market rising from USD 1.05 billion in 2024 to USD 2.83 billion by 2032, GLP-2 therapies are becoming critical to improving outcomes and reducing the long-term burden of intestinal failure.

Segmentation By Drug

  • Teduglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Online & Retail Pharmacies

By Geography

  • North America (By Drug, Route of Administration, Distribution Channel, and Country/ Sub-region)
    • U.S.
    • Canada
  • Europe (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • South Korea
    • Rest of Asia Pacific
  • Latin America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2024
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
  • 4.5. Regolatory and Reimbursement Scenario, By Key Countries/Region

5. Global GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Teduglutide
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Online & Retail Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Teduglutide
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Online & Retail Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Teduglutide
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online & Retail Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Teduglutide
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online & Retail Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Teduglutide
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online & Retail Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Teduglutide
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online & Retail Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Nestle
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Takeda Pharmaceutical Company Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. OxThera
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Zealand Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ironwood
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Hanmi Pharm Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Jaguar Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Merck KGaA
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. EnteraBio Ltd.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 2: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 6: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 7: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 10: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 11: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 14: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 18: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 22: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global GLP-2 Analogs Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global GLP-2 Analogs Market Value Share (%), by Drug, 2024 & 2032
  • Figure 3: Global GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global GLP-2 Analogs Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 7: North America GLP-2 Analogs Market Value Share (%), by Drug, 2024
  • Figure 8: North America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 9: North America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
  • Figure 10: North America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America GLP-2 Analogs Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America GLP-2 Analogs Market Value Share (%), By Country, 2024
  • Figure 14: Europe GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 15: Europe GLP-2 Analogs Market Value Share (%), by Drug, 2024
  • Figure 16: Europe GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 17: Europe GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
  • Figure 18: Europe GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 23: Asia Pacific GLP-2 Analogs Market Value Share (%), by Drug, 2024
  • Figure 24: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 25: Asia Pacific GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
  • Figure 26: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 31: Latin America GLP-2 Analogs Market Value Share (%), by Drug, 2024
  • Figure 32: Latin America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 33: Latin America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
  • Figure 34: Latin America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 39: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Drug, 2024
  • Figure 40: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 41: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
  • Figure 42: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global GLP-2 Analogs Market Share (%), By Company, 2024